FrancophonIA/ELRC3.0 huggingface dataset:
English: They are sold under several brand names including Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax and Ribomunyl.
Danish: De sælges under flere forskellige brandnavne, bl.a. Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax og Ribomunyl.
English: These medicines are taken by mouth (as capsules, tablets, granules/powder for making up an oral mixture or drops), dissolved under the tongue (as tablets), inhaled through the nose (as a liquid) or given by injection into a muscle or under the skin.
Danish: Disse lægemidler tages gennem munden (som kapsler, tabletter, granulater/pulver til fremstilling af en blanding til oral indtagelse eller dråber), opløses under tungen (som tabletter), inhaleres gennem næsen (som væske) eller gives ved injektion i en muskel eller under huden.
English: The review was carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's opinion.
Danish: Gennemgangen blev foretaget af Udvalget for Lægemidler til Mennesker (CHMP), der er ansvarligt for spørgsmål på dette område, og som vedtog agenturets udtalelse.
English: In the review, EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases.
Danish: Under gennemgangen undersøgte EMA's Udvalg for Lægemidler til Mennesker (CHMP) resultaterne af kliniske studier, data om indberettede bivirkninger ved disse lægemidler og rådgivning fra en ekspertgruppe om smitsomme sygdomme.
English: Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system to recognise and fight infections.
Danish: Bakterielysatholdige lægemidler er fremstillet af bakterieceller, der er blevet nedbrudt, og som skal stimulere immunsystemet til at genkende og bekæmpe infektioner.
English: • If you have an infection and are taking a bacterial lysate medicine to treat it, or if you are taking one of these medicines to prevent pneumonia, contact your doctor or pharmacist for advice on alternatives.
Danish: • Hvis du har en infektion og får et bakterielysat som behandling, eller hvis du tager et af disse lægemidler til forebyggelse af lungebetændelse, kan du kontakte din læge eller apotekspersonalet for at få vejledning om alternativer.
English: • The prescribing information of the medicines is being updated with the new indication and a warning against use for prevention of pneumonia.
Danish: • Informationen vedrørende ordinering af lægemidlerne er ved at blive opdateret med den nye indikation og en advarsel mod brug til forebyggelse af lungebetændelse.
English: On 27 June 2019, EMA recommended that bacterial lysate medicines authorised for respiratory conditions should only be used for the prevention of recurrent respiratory infections, with the exception of pneumonia.
Danish: Den 27. juni 2019 anbefalede EMA, at bakterielysatholdige lægemidler, der er godkendt til luftvejssygdomme, kun bør anvendes til forebyggelse af tilbagevendende luftvejsinfektioner, med undtagelse af lungebetændelse.
English: Although data are limited, the review found some evidence of effectiveness of these medicines in the prevention of recurrent respiratory tract infections and the safety profile is in line with what is expected for this type of product.
Danish: Selv om dataene er begrænsede, blev der under gennemgangen fundet belæg for, at disse lægemidler er effektive til at forebygge tilbagevendende infektioner i luftvejene, og sikkerhedsprofilen svarer til den, der forventes for denne type lægemiddel.
English: This followed a review that concluded that there are no robust data showing that these medicines are effective at treating existing respiratory infections, or for the prevention of pneumonia, therefore they should not be used for these purposes.
Danish: Dette skete efter en gennemgang, hvor det blev konkluderet, at der ikke findes fyldestgørende data, der viser, at disse lægemidler er effektive til behandling af eksisterende luftvejsinfektioner eller til forebyggelse af lungebetændelse, og at de derfor ikke bør anvendes til disse formål.
English: • Bacterial lysate medicines can continue to be used to prevent infections of the airways (except pneumonia) from coming back in patients who regularly get infections.
Danish: • Bakterielysatholdige lægemidler kan fortsat anvendes til at forhindre luftvejsinfektioner (bortset fra lungebetændelse) i at vende tilbage hos patienter, der regelmæssigt får infektioner.
English: • The indications of bacterial lysate medicines have been restricted to prophylaxis of recurrent respiratory tract infections, with the exception of pneumonia.
Danish: • Indikationerne for bakterielysatholdige lægemidler har været begrænset til profylakse af tilbagevendende luftvejsinfektioner, bortset fra lungebetændelse.
English: • Bacterial lysate medicines should not be used to treat existing infections of the airways or to prevent pneumonia (a lung infection) because there are not enough data to show that they work for these uses.
Danish: • Bakterielysatholdige lægemidler bør ikke anvendes til behandling af eksisterende luftvejsinfektioner eller til forebyggelse af lungebetændelse, da der ikke findes tilstrækkelige data til at påvise deres virkning ved disse anvendelser.
English: be prescribed for treatment of existing respiratory infections or for prophylaxis of pneumonia due to lack of efficacy data.
Danish: Bakterielysatholdige lægemidler bør ikke ordineres til behandling af eksisterende luftvejsinfektioner eller til profylakse af lungebetændelse på grund af manglende data om deres virkning.
English: Oral use blister (alu/PVC/PCT FE)
Danish: Oral anvendelse blister (alu/PVC/PCTFE)
English: 90 mg Film-coated tablet
Danish: 90 mg Filmovertrukket tablet
English: 1 x 2 tablets (unit dose)
Danish: 1 x 2 tabletter (enkeltdosis)
English: (Invented) name Strength Pharmaceutical Form
Danish: (Særnavn) Navn Styrke Lægemiddelform Administration Emballage
English: Further studies were carried out under laboratory conditions to confirm the other benefits of vaccination.
Danish: Yderligere studier blev gennemført i laboratorier for at bekræfte de andre fordele ved vaccination.
English: The vaccine helps to reduce the signs of these diseases.
Danish: Vaccinen medvirker til at mindske tegnene på disse sygdomme.
English: The first injection is given when the kitten is about eight weeks old, and the second three or four weeks later.
Danish: Den første injektion gives, når killingen er ca. 8 uger gammel, og den anden gives 3-4 uger senere.
English: Further information on Leucofeligen FeLV/RCP can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Danish: Yderligere information om Leucofeligen FeLV/RCP findes på agenturets websted under: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The contents of the two vials are mixed together before use to make up a suspension for injection.
Danish: Indholdet af de to hætteglas blandes før brug til en suspension til injektion.
English: In the future, the cat's immune system will be able to produce antibodies more quickly when it is exposed to the disease-causing forms of the viruses.
Danish: Derefter vil kattens immunsystem fremover kunne producere antistoffer hurtigere, hvis det udsættes for de sygdomsfremkaldende former af disse vira.
English: One year after the initial vaccination a booster vaccination should be given.
Danish: Et år efter den første injektion gives en booster-vaccination.
English: The most common side effects with Leucofeligen FeLV/RCP (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (<2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances.
Danish: De hyppigste bivirkninger ved Leucofeligen FeLV/RCP (der kan forekomme hos op til 1 ud af 10 katte) er en moderat og kortvarig lokal reaktion (< 2 cm) efter den første injektion, som fortager sig inden for 3-4 uger uden behandling, høj kropstemperatur (der varer 1-4 dage), mathed og fordøjelsesforstyrrelser.
English: The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant DNA technology'.
Danish: Det FeLV-protein, der anvendes i vaccinen, er ikke udtrukket fra vira, men er fremstillet i en bakterie ved hjælp af rekombinant dna-teknologi.
English: Because Leucofeligen FeLV/RCP is made up of two vaccines that have been available in the European Union (EU) since the 1980s (Feligen RCP and Leucogen), the company used data from studies carried out with these vaccines to support the use of Leucofeligen FeLV/RCP.
Danish: Da Leucofeligen FeLV/RCP består af to vacciner, som har været tilgængelige i EU siden 1980'erne (Feligen RCP og Leucogen), har virksomheden anvendt data fra studier af disse vacciner til at understøtte anvendelsen af Leucofeligen FeLV/RCP.
English: The vaccine also contains aluminium hydroxide and extract of Quillaja saponaria as adjuvants (ingredients that strengthen the immune response).
Danish: Vaccinen indeholder også aluminiumhydroxid og ekstrakt af Quillaja saponaria som adjuvanser (indholdsstoffer, der styrker immunforsvaret).
English: It also contains a protein of feline leukaemia virus (FeLV).
Danish: Den indeholder et protein fra felin leukæmivirus (FeLV).
English: Leucofeligen FeLV/RCP is a vaccine.
Danish: Leucofeligen FeLV/RCP er en vaccine.
English: The European Medicines Agency decided that Leucofeligen FeLV/RCP's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Leucofeligen FeLV/RCP opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: Leucofeligen FeLV/RCP contains small amounts of the three weakened viruses as listed above and a protein from the outer layer of FeLV called ‘envelope p45 protein'.
Danish: Leucofeligen FeLV/RCP indeholder små mængder af de tre førnævnte svækkede vira og et protein fra det ydre lag af FeLV (såkaldt "envelope p45-protein").
English: For more information about using Leucofeligen FeLV/RCP, see the package leaflet or contact your veterinarian or pharmacist.
Danish: Hvis du ønsker flere oplysninger om anvendelsen af Leucofeligen FeLV/RCP, kan du læse indlægssedlen eller kontakte din dyrlæge eller apoteket.
English: Leucofeligen FeLV/RCP should not be used in pregnant cats.
Danish: Leucofeligen FeLV/RCP bør ikke anvendes hos drægtige katte.
English: When a cat is given the vaccine, the immune system recognises the weakened viruses and the FeLV proteins as ‘foreign' and makes antibodies against them.
Danish: Når en kat får vaccinen, opfatter immunsystemet de svækkede vira og FeLV-proteinerne som "fremmede" og danner antistoffer mod dem.
English: The vaccine starts to protect against panleucopenia and leukaemia 3 weeks after the second injection and protection against calicivirosis and viral rhinotracheitis starts 4 weeks after the second injection.
Danish: Vaccinen begynder at beskytte mod panleucopeni og leukæmi 3 uger efter den anden injektion, og beskyttelsen mod calicivirus og viral rhinotracheitis begynder 4 uger efter den anden injektion.
English: Leucofeligen FeLV/RCP has been examined in two main ‘field' studies involving kittens aged eight to nine weeks.
Danish: Leucofeligen FeLV/RCP er blevet undersøgt i to primære feltstudier med killinger i alderen 8-9 uger.
English: The studies showed that Leucofeligen FeLV/RCP provided protection against the diseases listed above as measured by the presence of antibodies against the viruses in the vaccinated kittens' blood.
Danish: Studierne viste, at Leucofeligen FeLV/RCP yder beskyttelse mod de førnævnte sygdomme som målt ved forekomsten af antistoffer mod viraene i blodet hos de vaccinerede killinger.
English: The vaccine contains live feline viruses that have been attenuated (weakened) so they do not cause disease: feline calicivirus (strain F9), viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72).
Danish: Vaccinen indeholder levende feline vira, der er svækkede, så de ikke kan forårsage sygdom: felin calicivirus (stamme F9), viral rhinotracheitisvirus (stamme F2) og felin panleucopenivirus (stamme LR 72).
English: Leucofeligen FeLV/RCP is given to kittens as two injections under the skin.
Danish: Leucofeligen FeLV/RCP gives til killinger som to injektioner under huden.
English: In addition, it reduced the excretion of feline viral rhinotracheitis viruses, prevented a fall in white blood cell counts in feline panleucopenia and prevented FeLV from remaining in the blood.
Danish: Derudover reducerede vaccinen udskillelse af feline virale rhinotracheitisvira, forebyggede et fald i antallet af hvide blodlegemer ved felin panleucopeni og forhindrede FeLV i at forblive i blodet.
English: Leucofeligen FeLV/RCP is available as two vials, one containing a white powder pellet and one containing a liquid.
Danish: Leucofeligen FeLV/RCP fås som to hætteglas, hvor det ene indeholder en hvid pulverpellet og det andet en væske.
English: An overview of Leucofeligen FeLV/RCP and why it is authorised in the EU
Danish: En oversigt over Leucofeligen FeLV/RCP, og hvorfor det er godkendt i EU
English: It also prevents feline panleucopenia and persistent viraemia for feline leukaemia (the presence of feline leukaemia virus in the blood).
Danish: Den forebygger også felin panleucopeni og vedvarende viræmi ved felin leukæmi (forekomst af felin leukæmivirus i blodet).
English: For the full list of side effects and restrictions with Leucofeligen FeLV/RCP, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger og begrænsninger ved Leucofeligen FeLV/RCP fremgår af indlægssedlen.
English: Other information about Leucofeligen FeLV/RCP
Danish: Andre oplysninger om Leucofeligen FeLV/RCP
English: FeLV/RCP only every 3 years, with annual revaccination in intervening years with the vaccine Feligen RCP to protect against calicivirosis, rhinotracheitis and panleucopenia.
Danish: Derfor behøver ældre katte kun revaccination med Leucofeligen FeLV/RCP hvert 3. år med en årlig revaccination i de mellemliggende år med vaccinen Leucofeligen RCP for at beskytte mod calicivirus, rhinotracheitis og panleucopeni.
English: What is Leucofeligen FeLV/RCP and what is it used for?
Danish: Hvad er Leucofeligen FeLV/RCP, og hvad anvendes det til?
English: Its use is not recommended in cats nursing kittens.
Danish: Det frarådes at anvende vaccinen hos katte, der har killinger.
English: Why is Leucofeligen FeLV/RCP authorised in the EU?
Danish: Hvorfor blev Leucofeligen FeLV/RCP godkendt i EU?
English: Leucofeligen FeLV/RCP received a marketing authorisation valid throughout the EU on <date of issue of the Marketing Authorisation>.
Danish: Leucofeligen FeLV/RCP fik en markedsføringstilladelse med gyldighed i hele EU den 25. juni 2009.
English: Protection against leukaemia lasts for 3 years once a booster has been given and lasts for one year for calicivirosis and viral rhinotracheitis.
Danish: Beskyttelsen mod leukæmi varer i 3 år efter booster-vaccinationen, og beskyttelsen mod calicivirus og viral rhinotracheitis varer i 1 år.
English: What are the risks associated with Leucofeligen FeLV/RCP?
Danish: Hvilke risici er der forbundet med Leucofeligen FeLV/RCP?
English: How is Leucofeligen FeLV/RCP used?
Danish: Hvordan anvendes Leucofeligen FeLV/RCP?
English: Leucofeligen FeLV/RCP (Feline calicivirosis, feline viral rhinotracheitis, feline panleucopenia (live attenuated) and feline leukaemia (inactivated) vaccine)
Danish: felin viral rhinotracheitis (en influenzalignende sygdom, der skyldes et herpesvirus)
English: How does Leucofeligen FeLV/RCP work?
Danish: Hvordan virker Leucofeligen FeLV/RCP?
English: What benefits of Leucofeligen FeLV/RCP have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Leucofeligen FeLV/RCP?
English: Leucofeligen FeLV/RCP is a vaccine used to protect cats from eight weeks of age against the following diseases: feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus); feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus); feline panleucopenia (a serious illness causing bloody diarrhoea and a fall in white blood cell counts caused by a parvovirus); feline leukaemia (an illness affecting the immune system causing loss of appetite, weight loss, poor fur condition, fever, pale gums and diarrhoea caused by a retrovirus).
Danish: felin leukæmi (en sygdom, der rammer immunsystemet, og som medfører appetitløshed, vægttab, pelsproblemer, feber, blege gummer og diarré som følge af et retrovirus).
English: Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Danish: Bilag I FORTEGNELSE OVER LÆGEMIDLERNES NAVNE, LÆGEMIDDELFORM(ER), STYRKE(R), INDGIVELSESVEJ(E), INDEHAVER(E) AF MARKEDSFØRINGSTILLADELSE(R) I MEDLEMSSTATERNE
English: Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
Danish: Storbritannien Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
English: Levonorgestrel-containing emergency contraceptive medicinal products Member State (in EEA)
Danish: Levonorgestrel-holdige nødpræventive lægemidler
English: Belgium Sandoz N.V. Telecom Gardens Medialaan 40
Danish: Telecom Gardens Medialaan 40
English: Czech Republic Gedeon Richter Plc.
Danish: Storbritannien Gedeon Richter Plc.
English: Belgium Laboratoire HRA Pharma 15, rue Béranger
Danish: Grækenland Laboratoire HRA Pharma 15, rue Béranger
English: Luxembourg Laboratoire HRA Pharma 15, rue Béranger
Danish: Luxembourg Laboratoire HRA France 15, rue Béranger
English: HU-1103 Budapest Hungary
Danish: Gyömrői út 19-21 HU-1103 Budapest Hungary
English: NorLevo, tabletten 0,75 mg
Danish: NorLevo, tabletten 0,75 mg 0,75 mg Tablet
English: Laboratorios Leon Farma SA Calle La Vallina S/N Poligono Industrial Navatejera Navatejera, Leon E-24008 Spain
Danish: Laboratorios León Farma S.A. Calle La Vallina s/n Polígono Industrial Navatejera 24008 - Navatejera - León Spain
English: Norlevo 1500 microgramos comprimido
Danish: Norlevo 1500 microgramos comprimidos
English: Belgium Medimpex UK Limited 127 Shirland Road
Danish: Storbritannien Medimpex UK Limited 127 Shirland Road
English: Navela 0,75 mg Tabletten 0.75 mg
Danish: Navela 0,75 mg Tabletten 0,75 mg Tablet
English: Czech Republic Laboratorios León Farma S.A. Calle La Vallina s/n
Danish: Storbritannien Laboratorios Leon Farma SA Calle La Vallina S/N
English: Postinor 1500 microgramos comprimido
Danish: Postinor 1500 microgramos comprimidos
English: Postinor 1500 Mikrogramm-Tablette
Danish: Postinor 1500 MikrogrammTablette
English: Polígono Industrial Navatejera 24008 - Navatejera - León Spain
Danish: Poligono Industrial Navatejera Navatejera, Leon E-24008
English: EGIANTI 0,75 mg tablety 0.75 mg
Danish: EGIANTI 0,75 mg tablety
English: Empil 0,75 mg tabletta 0.75 mg
Danish: Empil 0,75 mg tabletta
English: Isteranda 1.5mg Tablets 1.5 mg
Danish: Isteranda 1.5mg Tablets
English: Ramonna 1,5 mg tableta 1.5 mg
Danish: Ramonna 1,5 mg tableta
English: Escapelle 1,5 mg tablets 1.5 mg
Danish: Escapelle 1,5 mg tablets
English: Nopregy 1,5 mg tablety 1.5 mg
Danish: Nopregy 1,5 mg tablety
English: NORLEVO 1.5 mg tablet 1.5 mg
Danish: NORLEVO 1.5 mg tablet
English: NORLEVO 1,5 mg, comprimé
Danish: NORLEVO 1,5 mg, comprimé 1,5 mg
English: Escapelle 1,5 mg tableta 1.5 mg
Danish: Escapelle 1,5 mg tableta
English: Gyömröí út 19-21
Danish: Gyömröí út 19-21 HU-1103 Budapest Hungary
English: PiDaNa 1,5 mg Tablette 1.5 mg
Danish: PiDaNa 1,5 mg Tablette
English: NORLEVO 1,5 mg tableta 1.5 mg
Danish: NORLEVO 1,5 mg tableta
English: Greece
Danish: Rumænien
English: Supportive data suggested that the benefit was maintained for up to two years.
Danish: Støttende data tydede på, at den gavnlige virkning varede ved i op til to år.
English: The recommended dose is 3 mg for each kg of bodyweight.
Danish: Den anbefalede dosis er 3 mg/kg legemsvægt.
English: The full EPAR for Cinqaero can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Cinqaero findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Cinqaero.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Cinqaero.
English: The medicine contains the active substance reslizumab.
Danish: Lægemidlet indeholder det aktive stof reslizumab.
English: Overall the medicine was well tolerated, and appropriate measures to monitor and manage risks have been put in place.
Danish: Overordnet tåltes lægemidlets godt, og der er iværksat passende foranstaltninger til at overvåge og håndtere risiciene.
English: Anaphylactic (severe allergic) reactions may affect less than 1 person in 100.
Danish: Svære allergiske (anafylaktiske) reaktioner kan forekomme hos mindre end 1 ud af 100 personer.
English: EMA/450050/2016 EMEA/H/C/003912
Danish: EMA/450050/2016 MEA/H/C/003912
English: Other information about Cinqaero
Danish: Andre oplysninger om Cinqaero
English: Cinqaero EMA/450050/2016
Danish: Cinqaero EMA/450050/2016x
English: Flare-ups were seen in 32% of patients (151 out of 477) given Cinqaero compared with 50% (237 out of 476) of those given placebo.
Danish: Opblussen sås hos 32 % (151 ud af 477) af de patienter, som fik Cinqaero, sammenholdt med 50 % (237 ud af 476) af dem, som fik placebo.
English: Cinqaero was compared with placebo (a dummy infusion), both given every 4 weeks for a year.
Danish: Cinqaero blev sammenlignet med en virkningsløs behandling (placebo), idet begge blev givet hver 4. uge gennem et år.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Cinqaero opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: What measures are being taken to ensure the safe and effective use of Cinqaero?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Cinqaero?
English: Why is Cinqaero approved?
Danish: Hvorfor blev Cinqaero godkendt?
English: This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.
Danish: Dette hjælper til at mindske inflammationen, så antallet af astmaanfald mindskes, og symptomerne bedres.
English: It is not intended to provide practical advice on how to use Cinqaero.
Danish: Det er ikke en praktisk vejledning i, hvordan Cinqaero bør anvendes.
English: What are the risks associated with Cinqaero?
Danish: Hvilke risici er der forbundet med Cinqaero?
English: What is Cinqaero and what is it used for?
Danish: Hvad er Cinqaero, og hvad anvendes det til?
English: The most common side effect with Cinqaero (which may affect about 2 people in 100) is an increase in levels of the enzyme creatine phosphokinase in the blood (a measure of possible damage to muscles).
Danish: Den hyppigste bivirkning ved Cinqaero (som kan forekomme hos omkring 2 ud af 100 personer) er en stigning i blodets indhold af enzymet kreatinfosfokinase (et mål for mulig muskelskade).
English: For more information about treatment with Cinqaero, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Cinqaero, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.